US Stock MarketDetailed Quotes

KNSA Kiniksa Pharmaceuticals International

Watchlist
  • 25.370
  • +0.340+1.36%
Trading May 15 12:29 ET
1.85BMarket Cap-105.71P/E (TTM)

About Kiniksa Pharmaceuticals International Company

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Company Profile

SymbolKNSA
Company NameKiniksa Pharmaceuticals International
Listing DateMay 24, 2018
Issue Price18.00
Founded2024
CEOMr. Sanj K. Patel
MarketNASDAQ
Employees315
Fiscal Year Ends12-31
Address23 Old Bond Street,3rd Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW1S 4PZ
Phone44-781-431-9100
Websitehttp://www.kiniksa.com

Company Executives

  • Name
  • Position
  • Salary
  • Sanj K. Patel
  • Chief Executive Officer and Chairman of the Board
  • 7.13M
  • Ross Moat
  • Executive Vice President and Chief Commercial Officer
  • 2.34M
  • Michael R. Megna
  • Chief Accounting Officer and Group Vice President, Finance
  • --
  • Mark Ragosa
  • Senior Vice President and Chief Financial Officer
  • 2.20M
  • Eben Tessari
  • Executive Vice President and Chief Operating Officer
  • 2.35M
  • Dr. John F. Paolini, M.D.
  • Executive Vice President and Chief Medical Officer
  • 2.43M
  • Tracey L. McCain, Esq.
  • Independent Director
  • 336.59K
  • Meta Cantey Boyd
  • Independent Director
  • 577.25K
  • Kimberly J. Popovits
  • Independent Director
  • 337.24K
  • Thomas R. Malley
  • Independent Director
  • 353.17K
  • G. Bradley Cole
  • Independent Director
  • 336.59K
  • Dr. Stephen R. Biggar,M.D.,PhD
  • Independent Director
  • 343.19K
  • Dr. Richard S. Levy,M.D.
  • Independent Director
  • 430.98K
  • Dr. Felix J. Baker,PhD
  • Lead Independent Director
  • 378.94K
  • Dr. Barry D. Quart,Pharm.D.
  • Independent Director
  • 350.77K

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

No. Symbol Price
Lennar Corp
LEN
109.715
Adobe
ADBE
403.530
Meritage Homes
MTH
67.815
4
Vale SA
VALE
9.875
5
Microsoft
MSFT
455.260
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call

Monetary Policy: Navigating the Fed's Rate Cut Cycle

Changing Fed policy is altering the market math for investors.